Lilly Covid-19 treatment could be authorised by September: Chief Scientist
Eli
Lilly and Co could have a drug specifically designed to treat COVID-19 authorized for use as early as September if
all goes well with either of two antibody therapies it is testing, its chief
scientist told Reuters on Wednesday.
Lilly
is also doing preclinical studies of a third antibody treatment for the illness
caused by the new coronavirus that could enter human clinical trials in the
coming weeks, Chief Scientific Officer Daniel Skovronsky said in an interview.
Lilly
has already launched human trials with two of the experimental therapies.
The
drugs belong to a class of biotech medicines called monoclonal antibodies
widely used to treat cancer, rheumatoid arthritis and many other conditions. A
monoclonal antibody drug developed against COVID-19 is likely to be more
effective than repurposed medicines currently being tested against the virus. Read More
Comments
Post a Comment